The Stop TB Partnership’s Global Drug Facility (GDF), housed and administered by the World Health Organization (WHO), is an innovative body created to provide eligible countries with access to sustainable tuberculosis (TB) control services ranging from grants to procurement to technical assistance and capacity building.

Since its inception in 2001, GDF has played a key role in the implementation of the WHO’s Stop TB Strategy and the Global Plan to Stop TB by supplying over 13 million patient treatments of first- and second-line anti-TB medicines, worth over USD $200 million, to more than 100 countries across the globe.
TRUST AND RECOGNITION

As the mandated procurement mechanism of the Stop TB Partnership and WHO for anti-TB health products, and with a reputation for excellence in providing sustainable TB control services, GDF enjoys close and enduring relationships with the world’s major donors and funding agencies. Organizations such as USAID, CIDA, DFID, the Global Fund and UNITAID have all recognized GDF’s commitment to the timely, transparent procurement of anti-TB commodities of the highest quality, entrusting GDF with generous ongoing funding and key partnerships that keep it at the forefront of the global fight against TB.

QUALITY BENCHMARK

GDF is the mandated procurement arm of the Green Light Committee (GLC) Initiative, which helps countries gain access to high-quality second-line anti-TB medicines. GLC is an internationally recognized benchmark for quality in MDR-TB treatment, housed by the WHO and supported by a host of renowned technical partners including the US Centers for Disease Control and Prevention (CDC), Médecins Sans Frontières (MSF) and the International Union Against Tuberculosis and Lung Disease (IUATLD).

MASSIVE SCALE-UP FOR MULTIDRUG-RESISTANT TB (MDR-TB)

Created to react quickly to changes in the TB landscape, GDF is taking a leading role in the global response to the growing threat of MDR-TB. With medicines of high quality, improved diagnosis and adherence to treatment regimens more important than ever, UNITAID has committed to invest more than US $150 million through GDF for a massive scale-up of approved MDR-TB programmes around the world from 2007-2011. UNITAID has committed almost US $9 million for a Strategic Rotating Stockpile of key second-line medicines and US $17.5 million for a Strategic Revolving Fund to provide eligible countries with provisional, reimbursable lines of credit in order to prevent bottlenecks.

QUALITY ASSURANCE

The GDF is committed to supplying first- and second-line anti-TB commodities of the highest quality. While preference in Expressions of Interest and tenders is given to WHO-prequalified products, the GDF’s Quality Assurance Policy also accepts two other quality assessment options:

• Option I: products with approval from a stringent national regulatory authority (such as the US Food and Drug Administration, EU, Japan, Canada)
• Option II: products that have passed an interim review by an Expert Review Panel from the WHO Prequalification Programme, and which are being assessed under the WHO Prequalification Programme

GDF conducts regular competitive processes for suppliers, such as Expressions of Interest and tenders, in order to increase access to GDF’s growing global market for newly qualified suppliers. GDF also facilitates access to the United States Pharmacopoeia (USP) Drug Quality Information programme and other initiatives to provide technical support for suppliers engaging the WHO Prequalification Programme.

TEAMWORK

GDF also works to develop long-term relationships with its suppliers, fostering an open and communicative environment where both parties work towards common and mutually beneficial goals. It holds regular meetings with all its supply partners - from procurement agents to suppliers and other contracted agents - to foster relationships and constantly improve the quality of its products and services. With GDF’s technical assistance to national TB programmes constantly improving the quality of forecast data from countries, contracted suppliers are provided with regular, detailed forecasts to aid production planning and manage demand.

LONG-TERM COUNTRY APPEAL

Key to GDF’s success has been the unique and comprehensive range of services it combines – from the provision and procurement of affordable, high-quality medicines and diagnostics equipment to technical assistance – which makes GDF an attractive one-stop TB solution for countries implementing the Stop TB Strategy, including DOTS, that lack these crucial elements in the fight against TB. Providing these integrated services means that GDF forges lasting relationships with the countries it supports with grants of free anti-TB medicines, often becoming the preferred direct procurement source for high-quality anti-TB commodities even after countries secure ongoing funding and develop sustainable, self-sufficient drug management practices.

PRODUCT CATALOGUE

GDF provides a comprehensive range of the WHO-approved anti-TB medicines and supplies needed to diagnose and treat both adult and paediatric patients infected with drug-sensitive and drug-resistant TB.

CONTACT US

For more information, please visit our website at www.stoptb.org/gdf or email us at gdf@who.int.

Benefits of being a GDF supplier:

• helping to save lives by playing an important role in the global fight against TB;
• access to a rapidly growing global market of first- and second-line anti-TB medicines and diagnostics;
• high visibility/status in the TB world through the GDF's close ties to the GLC and WHO as well as major donors and funding agencies;
• long-term exposure for a supplier’s brand as a source of medicines of known quality in GDF countries;
• partnership with an innovative, dynamic organization that fosters responsive, collaborative relationships with its suppliers;
• facilitated access to the United States Pharmacopoeia (USP) Drug Quality Information programme and other initiatives to provide technical support to suppliers engaging the WHO Prequalification Programme.

“The Global Drug Facility has been instrumental in the progress we are seeing today in global TB control. Lifesaving health commodities, when made available to people in need at the primary care level, can serve as a cornerstone for the entire health system. The GDF is an excellent example.”

Dr Margaret Chan, Director-General, World Health Organization